BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...
AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Datroway secures regulatory approvals in breast cancer across US and EU / 8 days
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 46 hrs
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 22 days
FDA advisory panel rejects camizestrant after SERENA‑6 results / 29 days
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days
UCB acquires Candid for $2B to pursue T‑cell engager therapies / 22 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medicare Advantage (not listed), Adolescent Health, Novo Nordisk, Cybersecurity and look for the RSS link.
StackHealth Time Machine